# Innoviva

> Innoviva is a VC fund backing Biotechnology and Health Diagnostics. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Brisbane, United States
- Total investments: 13
- Last investment: Apr 2026
- Lead investor: 77%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/innoviva
- Website: http://www.inva.com

Innoviva is a VC fund in Brisbane focused on Biotechnology and Health Diagnostics. Innoviva is committed to building long-lasting value and improving patient care, by partnering with companies that advance innovative therapies.Anchored by its respiratory assets, Innoviva blends a unique fusion of operational industry expertise and financial insight to create a solid foundation for capital returns—and carve a path towards ahealthier world for patients.

## Contacts

5 contacts available for Innoviva. Shizune tracks 4 team members at Innoviva. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/innoviva?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 38% |
| Health Diagnostics | 3 | 23% |
| Therapeutics | 2 | 15% |
| Medical | 1 | 8% |
| Wearables | 1 | 8% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 15% |
| Venture - Series Unknown | 2 | 15% |
| Series B | 1 | 8% |
| Post-IPO Debt | 1 | 8% |
| Post-IPO Equity | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 38% |
| Switzerland | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Eric d’Esparbes | Senior Vice President & Chief Financial Officer | 0 | https://shizune.co/investors/profile/eric-d-esparbes |
| George B. Abercrombie | Senior Vice President and Chief Commercial Officer | 0 | https://shizune.co/investors/profile/george-b-abercrombie-81c7 |
| Michael Faerm | Senior Vice President and Chief Business Officer | 0 | https://shizune.co/investors/profile/michael-faerm |
| Pavel Raifeld | CEO | 2 | https://shizune.co/investors/profile/pavel-raifeld |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Beacon Biosignals | Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $11M | Series B | Apr 06, 2026 |  |
| Beacon Biosignals | Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $86M | Series B | Nov 13, 2025 |  |
| Beacon Biosignals | Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $86M | Series B | Nov 13, 2025 |  |
| Armata Pharmaceuticals | Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections.Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which commoninfections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.The company was founded in 2005 and is based in Marina del Rey, CA, USA. | $15M | Post-IPO Debt | Aug 11, 2025 |  |
| Syndeio Biosciences | Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders. | $90M | Venture - Series Unknown | May 27, 2025 |  |
| Armata Pharmaceuticals | Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections.Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which commoninfections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.The company was founded in 2005 and is based in Marina del Rey, CA, USA. | $10M | Post-IPO Debt | Mar 12, 2025 |  |
| Armata Pharmaceuticals | Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections.Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which commoninfections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.The company was founded in 2005 and is based in Marina del Rey, CA, USA. | $35M | Post-IPO Debt | Mar 04, 2024 |  |
| Armata Pharmaceuticals | Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections.Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which commoninfections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.The company was founded in 2005 and is based in Marina del Rey, CA, USA. | $30M | Post-IPO Debt | Jan 10, 2023 |  |
| Gate Neurosciences | Gate Neurosciences is a healthcare company that offers neuroscience-related medical services. The company is developing the next-generation of targeted CNS therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. It was founded in 2018 and is headquartered in Carmel, IN, USA. | $25M | Venture - Series Unknown | Oct 05, 2022 |  |
| Nanolive | Nanolive SA was incorporated in November 2013 at the EPFL Innovation Park in Lausanne, Switzerland, by Dr. Yann Cotte (CEO) and Dr. Fatih Toy (scientific advisor), following the completion of their respective PhD theses at the EPFL Microsystems laboratory of Prof. Christian Depeursinge (Head of Scientific Advisory Board). | $2.2M | Series C | Sep 20, 2022 |  |

10 of 13 investments shown.

## Co-investors
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 3 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 3 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 3 deals together
- [Indicator Ventures](https://shizune.co/investors/profile/indicator-ventures) — VC Fund, 3 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital-6bb8) — VC Fund, 3 deals together
- [S32](https://shizune.co/investors/profile/section-32) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Innoviva invest in?

Innoviva invests primarily in Biotechnology, Health Diagnostics and Therapeutics startups, most often at Series C and Venture - Series Unknown stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Innoviva?

Public channels for Innoviva include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Innoviva?

The team at Innoviva includes Eric d’Esparbes (Senior Vice President & Chief Financial Officer), George B. Abercrombie (Senior Vice President and Chief Commercial Officer) and Michael Faerm (Senior Vice President and Chief Business Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co